FDA Approves Durvalumab for Muscle Invasive Bladder Cancer By Ogkologos - May 2, 2025 73 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and... July 27, 2018 ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany May 8, 2024 Plant-Based Diets and a New Treatment Combination for Prostate Cancer: Research... February 16, 2023 Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with... April 26, 2022 Load more HOT NEWS Liquid Biopsies on the Horizon for Children with Solid Cancers iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with... Why it’s difficult to estimate the number of extra cancer deaths... EMA Recommends Extension of Indications for Avelumab
